Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Alongside diabetes, Novo Nordisk 'poised for top spot in hemophilia'

This article was originally published in Scrip

Executive Summary

Not satisfied by being world's top diabetes company, Novo Nordisk is set to become the market leader in hemophilia as it builds on its leadership position in the factor VIIa segment and branches out with new offerings for hemophilia A and hemophilia B. This is the conclusion of a new report published by Datamonitor Healthcare entitled Key Companies in Hemophilia.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts